Back to Search Start Over

Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis.

Authors :
Feng X
Muller DC
Zahed H
Alcala K
Guida F
Smith-Byrne K
Yuan JM
Koh WP
Wang R
Milne RL
Bassett JK
Langhammer A
Hveem K
Stevens VL
Wang Y
Johansson M
Tjønneland A
Tumino R
Sheikh M
Johansson M
Robbins HA
Source :
EBioMedicine [EBioMedicine] 2023 Jun; Vol. 92, pp. 104623. Date of Electronic Publication: 2023 May 24.
Publication Year :
2023

Abstract

Background: To evaluate whether circulating proteins are associated with survival after lung cancer diagnosis, and whether they can improve prediction of prognosis.<br />Methods: We measured up to 1159 proteins in blood samples from 708 participants in 6 cohorts. Samples were collected within 3 years prior to lung cancer diagnosis. We used Cox proportional hazards models to identify proteins associated with overall mortality after lung cancer diagnosis. To evaluate model performance, we used a round-robin approach in which models were fit in 5 cohorts and evaluated in the 6th cohort. Specifically, we fit a model including 5 proteins and clinical parameters and compared its performance with clinical parameters only.<br />Findings: There were 86 proteins nominally associated with mortality (p < 0.05), but only CDCP1 remained statistically significant after accounting for multiple testing (hazard ratio per standard deviation: 1.19, 95% CI: 1.10-1.30, unadjusted p = 0.00004). The external C-index for the protein-based model was 0.63 (95% CI: 0.61-0.66), compared with 0.62 (95% CI: 0.59-0.64) for the model with clinical parameters only. Inclusion of proteins did not provide a statistically significant improvement in discrimination (C-index difference: 0.015, 95% CI: -0.003 to 0.035).<br />Interpretation: Blood proteins measured within 3 years prior to lung cancer diagnosis were not strongly associated with lung cancer survival, nor did they importantly improve prediction of prognosis beyond clinical information.<br />Funding: No explicit funding for this study. Authors and data collection supported by the US National Cancer Institute (U19CA203654), INCA (France, 2019-1-TABAC-01), Cancer Research Foundation of Northern Sweden (AMP19-962), and Swedish Department of Health Ministry.<br />Competing Interests: Declaration of interests Jian-Min Yuan has a declaration on NIH grant funding, and the other authors have no conflicts of interest.<br /> (Copyright © 2023 World Health Organization. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2352-3964
Volume :
92
Database :
MEDLINE
Journal :
EBioMedicine
Publication Type :
Academic Journal
Accession number :
37236058
Full Text :
https://doi.org/10.1016/j.ebiom.2023.104623